Skip to contentpdufa.bio

MIMRYLO (rusfertide): FDA NDA 220605

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 220605 is the FDA application for MIMRYLO (rusfertide). The FDA's Orange Book lists the applicant of record as TAKEDA PHARMACEUTICALS AMERICA INC and the first approval on it as Aug 28, 2026. Code name used in development: PTG-300. Owner today: Takeda Pharmaceutical Company Limited (NYSE: TAK).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 220605 · Orange Book NDA 220605

Names for this drug

Brand name (FDA)MIMRYLO
Orange Book trade name: MIMRYLO
Active ingredient (FDA)RUSFERTIDE ACETATE
Code namePTG-300
Source: Protagonist Therapeutics 10-K, Feb 28, 2022
“Our most advanced clinical asset, rusfertide (generic name for PTG-300), is an injectable hepcidin mimetic”

Who holds the application

FDA applicant of recordTAKEDA PHARMACEUTICALS AMERICA INC
FDA Orange Book data files as of Nov 13, 2026
Owner todayTakeda Pharmaceutical Company Limited (TAK)
Source: Takeda press release, Aug 28, 2026
“Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO” … “Takeda now has exclusive global development and commercialization rights for MIMRYLO.”
Earlier / partnerProtagonist Therapeutics (PTGX): licensed the drug to the current owner, Jan 31, 2024
Source: Takeda press release, Jan 31, 2024
“Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc., (Nasdaq: PTGX) today announced the signing” … “license and collaboration agreement for the development and commercialization of rusfertide”

Products on NDA 220605 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001MIMRYLOPOWDER;SUBCUTANEOUSEQ 9.5MG BASE/VIALAug 28, 2026
002MIMRYLOPOWDER;SUBCUTANEOUSEQ 19MG BASE/VIALAug 28, 2026
003MIMRYLOPOWDER;SUBCUTANEOUSEQ 28MG BASE/VIALAug 28, 2026
004MIMRYLOPOWDER;SUBCUTANEOUSEQ 41MG BASE/VIALAug 28, 2026
005MIMRYLOPOWDER;SUBCUTANEOUSEQ 54MG BASE/VIALAug 28, 2026

FDA decisions we track for this drug

Rusfertide - (REVIVE)PTGX · Decided

Drug page: /drug/rusfertide

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.